Alnylam Pharma (ALNY) Tops Q3 EPS by $2.38
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
Revenue Growth %: +15.3%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.3%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of $2.90, $2.38 better than the analyst estimate of $0.52. Revenue for the quarter came in at $1.25 billion versus the consensus estimate of $946.73 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
